Vertex Pharma COO Stuart Arbuckle disclosed in a regulatory filing that he had sold 4,295 shares of stock at $420.24 per share on February 12 for a total transaction amount of $1,804,931.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $465 from $420 at Argus
- Crispr Therapeutics price target lowered to $120 from $160 at Truist
- Vertex Pharmaceuticals price target lowered to $371 from $378 at Canaccord
- Vertex Pharmaceuticals price target raised to $472 from $446 at Barclays
- Tesla downgraded, UPS upgraded: Wall Street’s top analyst calls